Abstract

Oral administration of proteins and peptides is extremely difficult due to the nature of the digestive system, which is designed to break down polypeptides into amino acids before absorption. The low bioavailability of drugs is still an active area of research, and researchers have investigated several places in the gastrointestinal tract, but an important breakthrough that would be widely applicable to various proteins and peptides have not been achieved. Semaglutide is a recombinant long acting GLP-1 receptor agonist. Semaglutide is structurally represented as:

The present study aimed to develop and characterize a dosage form provides stabilized pharmaceutical compositions to enhance the pharmacokinetic profile of Semaglutide by using one or more permeation enhancers, along with pharmaceutically acceptable excipients and process for the preparation thereof, thereby reducing fluctuations in plasma concentration and improving bioavailability.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Download

Share

COinS